|
1
|
Jungk C, Chatziaslanidou D, Ahmadi R,
Capper D, Bermejo JL, Exner J, von Deimling A, Herold-Mende C and
Unterberg A: Chemotherapy with BCNU in recurrent glioma: Analysis
of clinical outcome and side effects in chemotherapy-naive
patients. BMC Cancer. 16:812016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wu CX, Lin GS, Lin ZX, Zhang JD, Chen L,
Liu SY, Tang WL, Qiu XX and Zhou CF: Peritumoral edema on magnetic
resonance imaging predicts a poor clinical outcome in malignant
glioma. Oncol Lett. 10:2769–2776. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang Y and Jiang T: Understanding high
grade glioma: Molecular mechanism, therapy and comprehensive
management. Cancer Lett. 331:139–146. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zheng H, Ying H, Yan H, Kimmelman AC,
Hiller DJ, Chen AJ, Perry SR, Tonon G, Chu GC, Ding Z, et al: Pten
and p53 converge on c-Myc to control differentiation, self-renewal,
and transformation of normal and neoplastic stem cells in
glioblastoma. Cold Spring Harb Symp Quant Biol. 73:427–437. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Stupp R, Hegi ME, Mason WP, van den Bent
MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B,
Belanger K, et al: Effects of radiotherapy with concomitant and
adjuvant temozolomide versus radiotherapy alone on survival in
glioblastoma in a randomised phase III study: 5-year analysis of
the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ohgaki H, Dessen P, Jourde B, Horstmann S,
Nishikawa T, Di Patre PL, Burkhard C, Schüler D, Probst-Hensch NM,
Maiorka PC, et al: Genetic pathways to glioblastoma: A
population-based study. Cancer Res. 64:6892–6899. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
He L and Hannon GJ: MicroRNAs: Small RNAs
with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lewis BP, Burge CB and Bartel DP:
Conserved seed pairing, often flanked by adenosines, indicates that
thousands of human genes are microRNA targets. Cell. 120:15–20.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jiang K, Zhi T, Xu W, Xu X, Wu W, Yu T,
Nie E, Zhou X, Bao Z, Jin X, et al: MicroRNA-1468-5p inhibits
glioma cell proliferation and induces cell cycle arrest by
targeting RRM1. Am J Cancer Res. 7:784–800. 2017.PubMed/NCBI
|
|
12
|
Yu L, Chen J, Liu Y, Zhang Z and Duan S:
MicroRNA-937 inhibits cell proliferation and metastasis in gastric
cancer cells by downregulating FOXL2. Cancer Biomark. 21:105–116.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xie Z, Chen W, Chen Y, Wang X, Gao W and
Liu Y: miR-768-3p is involved in the proliferation, invasion and
migration of non-small cell lung carcinomas. Int J Oncol.
51:1574–1582. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang X, Qiu LW, Peng C, Zhong SP, Ye L and
Wang D: MicroRNA-30c inhibits metastasis of ovarian cancer by
targeting metastasis-associated gene 1. J Cancer Res Ther.
13:676–682. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ganji SM, Saidijam M, Amini R,
Mousavi-Bahar SH, Shabab N, Seyedabadi S and Mahdavinezhad A:
Evaluation of MicroRNA-99a and MicroRNA-205 expression levels in
bladder cancer. Int J Mol Cell Med. 6:87–95. 2017.PubMed/NCBI
|
|
16
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hu Y, Li Y, Wu C, Zhou L, Han X, Wang Q,
Xie X, Zhou Y and Du Z: MicroRNA-140-5p inhibits cell proliferation
and invasion by regulating VEGFA/MMP2 signaling in glioma. Tumour
Biol. 39:10104283176975582017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li H, Yu L, Liu J, Bian X, Shi C, Sun C,
Zhou X, Wen Y, Hua D, Zhao S, et al: miR-320a functions as a
suppressor for gliomas by targeting SND1 and β-catenin, and
predicts the prognosis of patients. Oncotarget. 8:19723–19737.
2017.PubMed/NCBI
|
|
19
|
Su Y, Ni Z, Wang G, Cui J, Wei C, Wang J,
Yang Q, Xu Y and Li F: Aberrant expression of microRNAs in gastric
cancer and biological significance of miR-574-3p. Int
Immunopharmacol. 13:468–475. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ujihira T, Ikeda K, Suzuki T, Yamaga R,
Sato W, Horie-Inoue K, Shigekawa T, Osaki A, Saeki T, Okamoto K, et
al: MicroRNA-574-3p, identified by microRNA library-based
functional screening, modulates tamoxifen response in breast
cancer. Sci Rep. 5:76412015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tatarano S, Chiyomaru T, Kawakami K,
Enokida H, Yoshino H, Hidaka H, Nohata N, Yamasaki T, Gotanda T,
Tachiwada T, et al: Novel oncogenic function of mesoderm
development candidate 1 and its regulation by MiR-574-3p in bladder
cancer cell lines. Int J Oncol. 40:951–959. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Siebzehnrubl FA, Silver DJ, Tugertimur B,
Deleyrolle LP, Siebzehnrubl D, Sarkisian MR, Devers KG, Yachnis AT,
Kupper MD, Neal D, et al: The ZEB1 pathway links glioblastoma
initiation, invasion and chemoresistance. EMBO Mol Med.
5:1196–1212. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yue S, Wang L, Zhang H, Min Y, Lou Y, Sun
H, Jiang Y, Zhang W, Liang A, Guo Y, et al: miR-139-5p suppresses
cancer cell migration and invasion through targeting ZEB1 and ZEB2
in GBM. Tumour Biol. 36:6741–6749. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang S, Wang W, Liu G, Xie S, Li Q, Li Y
and Lin Z: Long non-coding RNA HOTTIP promotes hypoxia-induced
epithelial-mesenchymal transition of malignant glioma by regulating
the miR-101/ZEB1 axis. Biomed Pharmacother. 95:711–720. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pang H, Zheng Y, Zhao Y, Xiu X and Wang J:
miR-590-3p suppresses cancer cell migration, invasion and
epithelial-mesenchymal transition in glioblastoma multiforme by
targeting ZEB1 and ZEB2. Biochem Biophys Res Commun. 468:739–745.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ma J, Yao Y, Wang P, Liu Y, Zhao L, Li Z,
Li Z and Xue Y: MiR-152 functions as a tumor suppressor in
glioblastoma stem cells by targeting Kruppel-like factor 4. Cancer
Lett. 355:85–95. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Banelli B, Forlani A, Allemanni G,
Morabito A, Pistillo MP and Romani M: MicroRNA in Glioblastoma: An
Overview. Int J Genomics. 2017:76390842017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Huang SW, Ali ND, Zhong L and Shi J:
MicroRNAs as biomarkers for human glioblastoma: Progress and
potential. Acta Pharmacol Sin. 2018. View Article : Google Scholar
|
|
30
|
Areeb Z, Stylli SS, Koldej R, Ritchie DS,
Siegal T, Morokoff AP, Kaye AH and Luwor RB: MicroRNA as potential
biomarkers in Glioblastoma. J Neurooncol. 125:237–248. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xu H, Liu X, Zhou J, Chen X and Zhao J:
miR-574-3p acts as a tumor promoter in osteosarcoma by targeting
SMAD4 signaling pathway. Oncol Lett. 12:5247–5253. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Foss KM, Sima C, Ugolini D, Neri M, Allen
KE and Weiss GJ: miR-1254 and miR-574-5p: Serum-based microRNA
biomarkers for early-stage non-small cell lung cancer. J Thorac
Oncol. 6:482–488. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhou R, Zhou X, Yin Z, Guo J, Hu T, Jiang
S, Liu L, Dong X, Zhang S and Wu G: MicroRNA-574-5p promotes
metastasis of non-small cell lung cancer by targeting PTPRU. Sci
Rep. 6:357142016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhou R, Zhou X, Yin Z, Guo J, Hu T, Jiang
S, Liu L, Dong X, Zhang S and Wu G: Tumor invasion and metastasis
regulated by microRNA-184 and microRNA-574-5p in small-cell lung
cancer. Oncotarget. 6:44609–44622. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang X, Lu X, Geng Z, Yang G and Shi Y:
LncRNA PTCSC3/miR-574-5p governs cell proliferation and migration
of papillary thyroid carcinoma via Wnt/β-catenin signaling. J Cell
Biochem. 118:4745–4752. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ji S, Ye G, Zhang J, Wang L, Wang T, Wang
Z, Zhang T, Wang G, Guo Z, Luo Y, et al: miR-574-5p negatively
regulates Qki6/7 to impact β-catenin/Wnt signalling and the
development of colorectal cancer. Gut. 62:716–726. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li Q, Li X, Guo Z, Xu F, Xia J, Liu Z and
Ren T: MicroRNA-574-5p was pivotal for TLR9 signaling enhanced
tumor progression via down-regulating checkpoint suppressor 1 in
human lung cancer. PLoS One. 7:e482782012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shen A, Zhang Y, Yang H, Xu R and Huang G:
Overexpression of ZEB1 relates to metastasis and invasion in
osteosarcoma. J Surg Oncol. 105:830–834. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ma Y, Zheng X, Zhou J, Zhang Y and Chen K:
ZEB1 promotes the progression and metastasis of cervical squamous
cell carcinoma via the promotion of epithelial-mesenchymal
transition. Int J Clin Exp Pathol. 8:11258–11267. 2015.PubMed/NCBI
|
|
40
|
Larsen JE, Nathan V, Osborne JK, Farrow
RK, Deb D, Sullivan JP, Dospoy PD, Augustyn A, Hight SK, Sato M, et
al: ZEB1 drives epithelial-to-mesenchymal transition in lung
cancer. J Clin Invest. 126:3219–3235. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Jia B, Liu H, Kong Q and Li B:
Overexpression of ZEB1 associated with metastasis and invasion in
patients with gastric carcinoma. Mol Cell Biochem. 366:223–229.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Singh M, Spoelstra NS, Jean A, Howe E,
Torkko KC, Clark HR, Darling DS, Shroyer KR, Horwitz KB, Broaddus
RR and Richer JK: ZEB1 expression in type I vs type II endometrial
cancers: A marker of aggressive disease. Mod Pathol. 21:912–923.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ning Z, Wu K, Fan J, Wang B, Lv C, Zhu J,
Wang X, Hsieh JT and He D: Aberrant expressions of beta-catenin and
ZEB1 in bladder cancer and their significance. Xi Bao Yu Fen Zi
Mian Yi Xue Za Zhi. 30:1080–1083. 2014.(In Chinese). PubMed/NCBI
|
|
44
|
Song XF, Chang H, Liang Q, Guo ZF and Wu
JW: ZEB1 promotes prostate cancer proliferation and invasion
through ERK1/2 signaling pathway. Eur Rev Med Pharmacol Sci.
21:4032–4038. 2017.PubMed/NCBI
|
|
45
|
Lin J, Zhan Y, Liu Y, Chen Z, Liang J, Li
W, He A, Zhou L, Mei H, Wang F and Huang W: Increased expression of
ZEB1-AS1 correlates with higher histopathological grade and
promotes tumorigenesis in bladder cancer. Oncotarget.
8:24202–24212. 2017.PubMed/NCBI
|
|
46
|
Jägle S, Dertmann A, Schrempp M and Hecht
A: ZEB1 is neither sufficient nor required for
epithelial-mesenchymal transition in LS174T colorectal cancer
cells. Biochem Biophys Res Commun. 482:1226–1232. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Liu L, Tong Q, Liu S, Cui J, Zhang Q, Sun
W and Yang S: ZEB1 upregulates VEGF expression and stimulates
angiogenesis in breast cancer. PLoS One. 11:e01487742016.
View Article : Google Scholar : PubMed/NCBI
|
